| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ELAV-Like Protein 1 | 8 | 2021 | 30 | 1.980 |
Why?
|
| Lung Neoplasms | 21 | 2021 | 338 | 1.940 |
Why?
|
| RNA, Small Interfering | 13 | 2021 | 194 | 1.620 |
Why?
|
| Antineoplastic Agents | 16 | 2023 | 657 | 1.530 |
Why?
|
| Drug Delivery Systems | 15 | 2023 | 216 | 1.530 |
Why?
|
| Neoplasms | 12 | 2023 | 755 | 1.230 |
Why?
|
| Nanoparticles | 13 | 2020 | 273 | 1.210 |
Why?
|
| Radiation-Sensitizing Agents | 5 | 2017 | 32 | 1.210 |
Why?
|
| Radiation Tolerance | 8 | 2020 | 28 | 1.190 |
Why?
|
| DNA Damage | 7 | 2022 | 149 | 1.180 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 32 | 1.070 |
Why?
|
| Cell Line, Tumor | 25 | 2022 | 1259 | 1.040 |
Why?
|
| Exosomes | 7 | 2024 | 92 | 0.990 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 82 | 0.830 |
Why?
|
| Apoptosis | 13 | 2021 | 739 | 0.780 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 143 | 0.700 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 16 | 0.690 |
Why?
|
| Pyridines | 2 | 2020 | 99 | 0.660 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2017 | 102 | 0.640 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 143 | 0.630 |
Why?
|
| Interleukins | 7 | 2021 | 108 | 0.630 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 442 | 0.560 |
Why?
|
| Enzyme Inhibitors | 5 | 2006 | 247 | 0.550 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2017 | 34 | 0.540 |
Why?
|
| Humans | 46 | 2024 | 26829 | 0.540 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2006 | 26 | 0.510 |
Why?
|
| DNA Repair | 6 | 2008 | 81 | 0.500 |
Why?
|
| Cell Proliferation | 8 | 2022 | 771 | 0.490 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 284 | 0.440 |
Why?
|
| Cisplatin | 4 | 2020 | 172 | 0.440 |
Why?
|
| Drug Carriers | 4 | 2023 | 109 | 0.430 |
Why?
|
| Cell Movement | 7 | 2022 | 353 | 0.390 |
Why?
|
| Melanoma | 4 | 2006 | 128 | 0.380 |
Why?
|
| Nanomedicine | 4 | 2021 | 62 | 0.360 |
Why?
|
| Dendrimers | 3 | 2020 | 15 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 444 | 0.360 |
Why?
|
| Hydroxamic Acids | 3 | 2006 | 18 | 0.350 |
Why?
|
| Polymers | 3 | 2017 | 114 | 0.340 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 377 | 0.340 |
Why?
|
| Histones | 2 | 2006 | 90 | 0.320 |
Why?
|
| Cell Survival | 6 | 2017 | 394 | 0.310 |
Why?
|
| Folate Receptor 1 | 2 | 2017 | 10 | 0.280 |
Why?
|
| RNAi Therapeutics | 2 | 2016 | 13 | 0.270 |
Why?
|
| Doxorubicin | 2 | 2016 | 74 | 0.260 |
Why?
|
| Genetic Therapy | 3 | 2017 | 116 | 0.240 |
Why?
|
| Endocytosis | 2 | 2022 | 81 | 0.230 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2021 | 37 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 563 | 0.220 |
Why?
|
| Radiation, Ionizing | 3 | 2016 | 25 | 0.220 |
Why?
|
| NF-kappa B | 1 | 2004 | 187 | 0.220 |
Why?
|
| Gene Expression Regulation | 2 | 2022 | 623 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2021 | 134 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 124 | 0.200 |
Why?
|
| Adenoviridae | 5 | 2007 | 65 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2022 | 95 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 104 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2022 | 134 | 0.190 |
Why?
|
| Female | 6 | 2024 | 14463 | 0.190 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 288 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2021 | 41 | 0.180 |
Why?
|
| Immunity | 1 | 2021 | 26 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2021 | 85 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 310 | 0.170 |
Why?
|
| Blotting, Western | 5 | 2015 | 503 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 30 | 0.170 |
Why?
|
| Liposomes | 2 | 2017 | 142 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 207 | 0.160 |
Why?
|
| Comet Assay | 2 | 2016 | 5 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2022 | 465 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 147 | 0.150 |
Why?
|
| Cell Cycle | 3 | 2015 | 155 | 0.150 |
Why?
|
| Chitosan | 2 | 2017 | 31 | 0.150 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 278 | 0.150 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 66 | 0.150 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 10 | 0.150 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 5 | 0.150 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 22 | 0.150 |
Why?
|
| Caspases | 1 | 2017 | 43 | 0.140 |
Why?
|
| Mitochondria | 2 | 2017 | 334 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2017 | 32 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 52 | 0.140 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 20 | 0.140 |
Why?
|
| Oncogenes | 1 | 2017 | 34 | 0.140 |
Why?
|
| MicroRNAs | 2 | 2021 | 280 | 0.140 |
Why?
|
| HMGA1a Protein | 1 | 2016 | 4 | 0.140 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2016 | 14 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2015 | 110 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2017 | 183 | 0.140 |
Why?
|
| Autophagy | 1 | 2017 | 71 | 0.130 |
Why?
|
| Ku Autoantigen | 2 | 2006 | 12 | 0.130 |
Why?
|
| Antigens, Nuclear | 2 | 2006 | 22 | 0.130 |
Why?
|
| Acetylation | 2 | 2006 | 36 | 0.130 |
Why?
|
| Cell Line | 4 | 2005 | 673 | 0.130 |
Why?
|
| Lipids | 1 | 2017 | 195 | 0.130 |
Why?
|
| Nanotubes | 1 | 2015 | 15 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 2015 | 15 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 27 | 0.130 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 128 | 0.120 |
Why?
|
| Animals | 10 | 2021 | 9963 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 100 | 0.120 |
Why?
|
| Gold | 1 | 2015 | 129 | 0.120 |
Why?
|
| Technology, Pharmaceutical | 1 | 2014 | 9 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2014 | 89 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 63 | 0.110 |
Why?
|
| Fibroblasts | 3 | 2016 | 152 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 12 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 481 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2016 | 624 | 0.100 |
Why?
|
| Transfection | 4 | 2007 | 313 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 180 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2015 | 197 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 205 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2004 | 36 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 80 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2006 | 98 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 586 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2016 | 262 | 0.080 |
Why?
|
| Folic Acid | 2 | 2020 | 31 | 0.070 |
Why?
|
| Mesoderm | 1 | 2007 | 12 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 31 | 0.070 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 21 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2021 | 1344 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2017 | 63 | 0.070 |
Why?
|
| Stem Cells | 1 | 2007 | 113 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2004 | 135 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2006 | 14 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 144 | 0.070 |
Why?
|
| Receptors, Transferrin | 2 | 2017 | 17 | 0.070 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2006 | 1 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2006 | 9 | 0.070 |
Why?
|
| Caspase 9 | 2 | 2016 | 16 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 49 | 0.070 |
Why?
|
| Drug Liberation | 2 | 2016 | 23 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 146 | 0.070 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2006 | 7 | 0.070 |
Why?
|
| Doxycycline | 2 | 2016 | 19 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 7 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 2006 | 18 | 0.070 |
Why?
|
| Cell Death | 2 | 2016 | 110 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 122 | 0.060 |
Why?
|
| Butyrates | 1 | 2005 | 13 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2005 | 22 | 0.060 |
Why?
|
| Kinetics | 2 | 2016 | 538 | 0.060 |
Why?
|
| Triglycerides | 1 | 2005 | 117 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 151 | 0.060 |
Why?
|
| Leupeptins | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 13 | 0.060 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2004 | 11 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2004 | 31 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 24 | 0.060 |
Why?
|
| Benzamides | 1 | 2004 | 33 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 93 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 83 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 106 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2015 | 560 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 27 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 68 | 0.050 |
Why?
|
| DNA | 1 | 2004 | 365 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 143 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 243 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2017 | 313 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 110 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2021 | 25 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2017 | 107 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 251 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 8 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 8 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 24 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 32 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 57 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 77 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 105 | 0.040 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2020 | 7 | 0.040 |
Why?
|
| Time Factors | 1 | 2004 | 1562 | 0.040 |
Why?
|
| Mice | 4 | 2016 | 4408 | 0.040 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2020 | 6 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 270 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 22 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 189 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2020 | 80 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2020 | 93 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 349 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 206 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 16 | 0.040 |
Why?
|
| G1 Phase | 1 | 2017 | 15 | 0.040 |
Why?
|
| Static Electricity | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 30 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2017 | 132 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2016 | 15 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 135 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 131 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 168 | 0.030 |
Why?
|
| Transferrin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 19 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2016 | 151 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 67 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 261 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 182 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 129 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 68 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 253 | 0.030 |
Why?
|
| Fluorescamine | 1 | 2014 | 2 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 324 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 34 | 0.030 |
Why?
|
| Polyesters | 1 | 2014 | 33 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 26 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 96 | 0.030 |
Why?
|
| Plasmids | 1 | 2014 | 122 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 68 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 93 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 646 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2012 | 4 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 5 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 472 | 0.030 |
Why?
|
| Curcumin | 2 | 2003 | 67 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 496 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2008 | 6 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 17 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 49 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2008 | 39 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 23 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 122 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 264 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Purines | 1 | 2006 | 14 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 22 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 15 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 30 | 0.020 |
Why?
|
| Granzymes | 1 | 2006 | 2 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 60 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cell Division | 1 | 2006 | 153 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 62 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 150 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 228 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 118 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2004 | 25 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 21 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Anisomycin | 1 | 2003 | 3 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2003 | 10 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 4 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2003 | 5 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 13 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 408 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 33 | 0.010 |
Why?
|
| Glioma | 1 | 2004 | 117 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2003 | 33 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 25 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 176 | 0.010 |
Why?
|
| Nocodazole | 1 | 2002 | 11 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2002 | 12 | 0.010 |
Why?
|
| G2 Phase | 1 | 2002 | 15 | 0.010 |
Why?
|
| Imidazoles | 1 | 2003 | 60 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 19 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 36 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 93 | 0.010 |
Why?
|
| Mitosis | 1 | 2002 | 109 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 139 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 240 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 197 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2004 | 324 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1394 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 817 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 509 | 0.010 |
Why?
|
| Male | 2 | 2004 | 12870 | 0.010 |
Why?
|